Innovative Anti-Cancer Compounds’ Effects on Cancers (eRaDicate)
European Union
Project Duration: 01.01.2024 - 31.12.2027
About the project
Programme
Marie Sklodowska Curie Actions Doctoral Network funded by the European Union
Project lead
Medical University of Vienna, Priv.-Doz. Mag. Dr. Martin Schepelmann
Project partners
https://www.eradicate-project.eu/consortium/
https://cordis.europa.eu/project/id/101119427
Danube Private University (DPU) is a non-beneficiary partner
DPU representative in this project: Assoz.-Prof. Priv.-Doz. Amirreza Mahbod, PhD
Project summary
Innovative anti-cancer compounds’ effects on cancers
The ‘eRaDicate’ international programme will empower 10 young scientists in cancer research, with a focus on therapies for stem cell-driven relapse and metastasis. Key targets include nuclear receptors such as the retinoic acid receptor (RAR) and the vitamin D receptor (VDR). Supported by the Marie Skłodowska-Curie Actions programme, the eRaDicate project will evaluate compounds that target RAR and VDR for their anti-cancer effects. The project will develop a dual-action hybrid compound that acts as an antagonist of RARγ and an agonist of VDR, along with pre-formulation strategies. This research will investigate the impact of these compounds on stemness and metastasis in leukaemia, breast, prostate, colorectal, and ovarian cancers, and assess the effectiveness of the pan-RAR antagonist in combating chemotherapy-induced neutropenia.
Assoc.-Prof. Priv.-Doc. Amirreza Mahbod from Danube Private University (DPU), an expert in computer vision, machine learning, and deep learning—particularly in the field of computational pathology—co-supervises a doctoral student at TissueGnostics within Research Project 7, titled “Plasmonic Tissue Cytometry.”